Aspira Women’s Health CEO departs; chair named interim

Aspira Women’s Health Inc. announced a leadership change, with Michael Buhle ceasing to serve as Chief Executive Officer on June 17, 2026.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aspira Women’s Health Inc. announced a leadership change, with Michael Buhle ceasing to serve as Chief Executive Officer on June 17, 2026. The board appointed its Chairman, John Fraser, as Interim Chief Executive Officer and Principal Executive Officer while it conducts a search of internal and external candidates.

The company states that Mr. Buhle’s departure was not due to any disagreement about operations, policies, or practices. Aspira and Mr. Buhle are discussing a separation agreement, and the company plans to file an amendment disclosing the material terms within four business days after they are determined.

Positive

None.

Negative

CEO transition introduces leadership uncertainty, as Michael Buhle ceased serving as Chief Executive Officer on June 17, 2026 and an interim leader was appointed while a permanent replacement is sought.

Insights

CEO departs; board chair steps in as interim leader while a successor search begins.

The change from Michael Buhle to John Fraser as Interim CEO and Principal Executive Officer on June 17, 2026 is a notable governance event. Concentrating both the chair and interim CEO roles in one person can streamline decisions but also reduces separation between oversight and management.

The filing notes that Mr. Buhle’s departure is not tied to disagreements on operations, policies, or practices, which tempers concern. A separation agreement is still being negotiated, and an amended disclosure will outline material terms once finalized, giving more clarity on cost and conditions around the transition.

Mr. Fraser’s background at Seamark Capital and his existing role as board chair suggest familiarity with Aspira’s strategy. The eventual appointment of a permanent CEO, once the internal and external search concludes, will be the key milestone shaping longer-term leadership stability.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

CEO transition date: June 17, 2026 Interim CEO appointment date: June 17, 2026 Interim CEO age: 66 years +1 more

4 metrics

CEO transition date June 17, 2026 Date Michael Buhle ceased serving as Chief Executive Officer

Interim CEO appointment date June 17, 2026 Date John Fraser was appointed Interim CEO and Principal Executive Officer

Interim CEO age 66 years Age of John Fraser as disclosed in the filing

Filing signature date June 22, 2026 Date the report was signed by the Chief Financial Officer

Key Terms

Interim Chief Executive Officer, Principal Executive Officer, separation agreement, Emerging Growth Company

4 terms

Interim Chief Executive Officer financial

"appointed John Fraser, the Company’s current Chairman of the Board, to serve as its Interim Chief Executive Officer"

An interim chief executive officer is a temporary leader appointed to run a company while the board searches for a permanent CEO or manages an unexpected departure. Investors pay attention because this person shapes near-term strategy, stability and market confidence—like a substitute driver steering the car until the regular driver returns—and their actions and credibility can influence share price, hiring and major deals.

Principal Executive Officer financial

"Mr. Fraser will also serve as the Company’s Principal Executive Officer"

The principal executive officer is the highest-ranking manager who leads a company’s overall strategy, operations and public communication—often acting like the captain of a ship who sets direction and makes final calls. Investors watch this person because their decisions, credibility and ability to deliver results shape company performance, risk and market confidence, and changes in that role can directly affect stock value and corporate accountability.

separation agreement financial

"The Company and Mr. Buhle are discussing a separation agreement in connection with his departure"

A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.

Emerging Growth Company regulatory

"Emerging Growth Company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Aspira Women’s Health (AWHL) disclose?

Aspira Women’s Health disclosed that Michael Buhle ceased serving as Chief Executive Officer on June 17, 2026. The board appointed Chairman John Fraser as Interim Chief Executive Officer and Principal Executive Officer while it conducts a search for a permanent CEO.

Who is John Fraser, the new Interim CEO of Aspira Women’s Health (AWHL)?

John Fraser is the company’s Chairman of the Board and now Interim Chief Executive Officer and Principal Executive Officer. He co-founded Seamark Capital and holds business and finance degrees from Bowling Green State University and The Ohio State University, respectively.

Did Michael Buhle leave Aspira Women’s Health (AWHL) after a disagreement?

The company states that Michael Buhle’s departure as Chief Executive Officer was not due to any disagreement on operations, policies, or practices. This language is intended to clarify that his exit is not linked to reported internal disputes or strategic conflicts.

Will Aspira Women’s Health (AWHL) file a separation agreement with former CEO Buhle?

Aspira and former CEO Michael Buhle are discussing a separation agreement, but terms were not finalized as of the filing date. The company plans to amend the report within four business days after terms are determined to disclose material separation details.

How long will John Fraser serve as Interim CEO of Aspira Women’s Health (AWHL)?

John Fraser will serve as Interim Chief Executive Officer while the board conducts a search of internal and external candidates. The filing does not specify an end date, indicating his role continues until a permanent CEO is selected and appointed.

Are there any special arrangements behind John Fraser’s appointment at Aspira Women’s Health (AWHL)?

The filing states there are no arrangements or understandings with any other persons pursuant to which John Fraser was appointed to his positions. It also notes there are no family relationships between him and any Aspira director or executive officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 09:13 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 17, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware		001-34810		33-0595156
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation or organization)		File Number)		Identification No.)

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	AWHL	OTC QX Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company"). Effective June 17, 2026, the board of directors (the “Board”) of the Company appointed John Fraser, the Company’s current Chairman of the Board, to serve as its Interim Chief Executive Officer while a search of internal and external candidates is conducted. Mr. Fraser will also serve as the Company’s Principal Executive Officer.

Mr. Buhle’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company and Mr. Buhle are discussing a separation agreement in connection with his departure, but the terms have not been finalized as of the date of this Current Report on Form 8-K. The Company will amend this Current Report on Form 8-K to disclose any additional information required by Item 5.02, including the material terms of any separation agreement, within four business days after such information is determined or becomes available.

Mr. Fraser, age 66, is the co-founder and co-portfolio manager of Seamark Capital, a fundamentals-based proprietary research growth equities asset management advisor. Mr. Fraser holds a B.S. in Business Administration with emphasis in Economics from Bowling Green State University, and an MBA with emphasis in Finance from The Ohio State University.

There are no arrangements or understandings between Mr. Fraser and any other persons pursuant to which he was appointed to his positions with the Company. There are no family relationships between Mr. Fraser and any director or executive officer of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: June 22, 2026


	ASPIRA WOMEN’S HEALTH INC.

	By:	/s/ John Strahley
	Name:	John Strahley
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Aspira Women’s Health CEO departs; chair named interim